LeMaitre Vascular (LMAT) to Release Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) is projected to release its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of $0.50 per share and revenue of $57.61 million for the quarter. LeMaitre Vascular has set its FY 2025 guidance at 2.150-2.320 EPS and its Q1 2025 guidance at 0.480-0.530 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. The company had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Trading Down 0.1 %

Shares of LMAT opened at $91.54 on Tuesday. The firm has a market cap of $2.07 billion, a P/E ratio of 50.02, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The company’s 50-day moving average price is $86.67 and its 200 day moving average price is $93.46. LeMaitre Vascular has a 12-month low of $64.44 and a 12-month high of $109.58.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.87%. The ex-dividend date was Thursday, March 13th. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Wall Street Analyst Weigh In

A number of brokerages have commented on LMAT. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.14.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at $456,915.68. This represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.